Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance

International Journal of Cancer

Volumn 138, Issue 7, 2016, Pages 1645-1656

  Wojtuszkiewicz, Anna ^a,b   Raz, Shachar ^c   Stark, Michal ^c   Assaraf, Yehuda G ^c   Jansen, Gerrit ^b   Peters, Godefridus J ^b   Sonneveld, Edwin ^d   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a,b  

^a University of Amsterdam   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Dutch Childhood Oncology Group DCOG   (Netherlands)

Author keywords

acute lymphoblastic leukemia; alternative splicing; drug resistance; folylpolyglutamate synthetase; methotrexate

Indexed keywords

ANTINEOPLASTIC AGENT; METHOTREXATE; PEPTIDE SYNTHASE; TETRAHYDROFOLATE SYNTHASE;

ADULT; ALTERNATIVE RNA SPLICING; CHILD; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; METHOTREXATE; PEPTIDE SYNTHASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84955620795     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29919     Document Type: Article

References (51)

1. Escherich G, Horstmann MA, Zimmermann M, et al., Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia 2010; 24: 298-308.
2. Einsiedel HG, Von Stackelberg A, Hartmann R, et al., Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23: 7942-50.
3. Rots M, Pieters R, Kaspers G, et al., Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000; 110: 791-800.
4. Stokstad ELR., Historical perspectives on key advances in the biochemistry and physiology of folates. In:, Picciano MF, Stokstad ELR, Gregory JF, eds. Evaluation of folic acid metabolism in health and disease. New York, NY: Wiley Periodicals. 1990. 1-21.
5. Gonen N, Assaraf YG., Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012; 15: 183-210.
6. Li JC, Kaminskas E., Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci USA 1984; 81: 5694-8.
7. Assaraf YG., Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26: 153-81.
8. Assaraf Y., The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9: 227-46.
9. Allegra CJ, Hoang K, Yeh GC, et al., Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987; 262: 13520-6.
10. Baggott JE, Vaughn WH, Hudson BB., Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236: 193-200.
11. Masson E, Relling MV, Synold TW, et al., Accumulation of Methotrexate Polyglutamates in Lymphoblasts Is a Determinant of Antileukemic Effects In Vivo. J Clin Invest 1996; 97: 73-80.
12. Whitehead VM, Rosenblatt DS, Vuchich MJ, et al., Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990; 76: 44-9.
13. Mauritz R, Peters GJ, Priest DG, et al., Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002; 63: 105-15.
14. Fotoohi K, Jansen G, Assaraf YG, et al., Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 2004; 104: 4194-201.
15. Barnes M, Estlin E, Taylor G., Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in. Clin Cancer Res 1999; 5: 2548-58.
16. Rots MG, Pieters R, Peters GJ, et al., Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 1999; 93: 1677-83.
17. Raz S, Stark M, Assaraf Y., Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia. Oncotarget 2014; 15: 9183-98.
18. McCloskey D, McGuire J, Russell C, Rowan B, Bertino J, Pizzorno G, Mini E., Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 1991; 266: 6181-7.
19. Drake J, Allegra C., Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 1996; 51: 1349-55.
20. Lu K, Yin M-B, Mcguire JJ, et al., Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileaocecal adenocarcinoma cell line. Biochem Pharmacol 1995; 50: 391-8.
21. Pizzorno G, Moroson B, Cashmore A., Multifactorial resistance to 5, 10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995; 55: 566-73.
22. Leil TA, Endo C, Adjei AA, et al., a Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 2007; 67: 8772-82.
23. Leclerc GJ, York Ta, Hsieh-Kinser T, et al., Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line. Leuk Res 2007; 31: 293-9.
24. Roy K, Egan M, Sirlin S, et al., Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene Expression in Some Folate Analogue-resistant Variants of the L1210 Cell. J Biol Chem 1997; 272: 6903-8.
25. Stark M, Wichman C, Avivi I, et al., Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113: 4362-9.
26. Fotoohi AK, Assaraf YG, Moshfegh A, et al., Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol 2009; 77: 1410-7.
27. McGuire J, Haile W, Russell C, et al., Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure. Oncol Res 1995; 7: 535-43.
28. Mauritz R, Bekkenk M, Rots M, et al., Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 1998; 4: 2399-410.
29. Desmet F-O, Hamroun D, Lalande M, et al., Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009; 37: e67
30. Sun X, Cross JA, Bognar AL, et al., A Folate-binding triggers the activation of folylpolyglutamate synthetase. J Mol Biol 2001; 310: 1067-78.
31. Jansen G, Schornagel J, Kathmann I, et al., Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res 1992; 4: 299-305.
32. Van Meerloo J, Kaspers G, Cloos J., Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731: 237-45.
33. Sanghani SP, Sanghani PC, Moran RG., Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-gamma-glutamate synthetase by site-directed mutagenesis. J Biol Chem 1999; 274: 27018-27.
34. Schwerk C, Schulze-Osthoff K., Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19: 1-13.
35. Huang T, Myklebust LM, Kjarland E, et al., LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer 2007; 6: 31
36. McGuire J, Heitzman K, Haile W, et al., Cross-resistance studies of folyl-polyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. Leukemia 1993; 7: 1996-2003.
37. Freemantle S, Taylor S, Krystal M, et al., Upstream organization of and multiple transcripts from the human folylpoly-glutamate synthetase gene. J Biol Chem 1995; 270: 9579-84.
38. Leclerc G, Barredo J., Folylpolyglutamate synthetase gene mRNA splice variants and protein expression in primary human leukaemia cells, cell lines and normal human tissues. Clin Cancer Res 2001; 7: 942-51.
39. Turner FB, Taylor SM, Moran RG., Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 2000; 275: 35960-8.
40. Pommier Y, Leo E, Zhang H, Marchand C., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421-33.
41. Pang B, Qiao X, Janssen L, et al., Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013; 4: 1908
42. Mikita T, Beardsley GP., Effects of arabinosylcytosine-substituted DNA on DNA/RNA hybrid stability and transcription by T7 RNA polymerase. Biochemistry 1994; 33: 9195-208.
43. Lents N, Wheeler L, Baldassare J, Dynlacht B., Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. Cell Cycle 2008; 7: 1580-6.
44. Laane E, Tamm KP, Buentke E, et al., Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009; 16: 1018-29.
45. Distelhorst CW., Recent insights into the mechanism of glucocorticosteroid- induced apoptosis. Cell Death Differ 2002; 9: 6-19.
46. Raz S, Sheban D, Gonen N, et al., Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest. Cell Death Dis 2014; 5: e1067
47. Wojtuszkiewicz A, Assaraf YG, Maas M, et al., Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. Exp Opin Drug Metab Toxicol 2015; 11: 673-89.
48. Veuger MJT., Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood 2002; 99: 1373-80.
49. Corsini L, Bonnal S, Bonna S, et al., U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat Struct Mol Biol 2007; 14: 620-9.
50. Moore MJ, Wang Q, Kennedy CJ, et al., An alternative splicing network links cell-cycle control to apoptosis. Cell 2010; 142: 625-36.
51. Stark M, Bram EE, Akerman M, et al., Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance. J Biol Chem 2011; 286: 3741-54.